This study demonstrates the combined effect of the angiogenic proteins, hVEGF and hAng-1, coencapsulated in human serum albumin (HSA) nanoparticles (NPs), towards human umbilical vein endothelial cells (HUVECs) and an evaluation of the potential application of this delivery system towards therapeutic angiogenesis. The application of this NP system enabled efficient, controlled and extended release of the encapsulated proteins. The size of the NPs cross-linked with glutaraldehyde varied between 101.0± 0.9nm and zeta potential was found to be -18± 2.9 mV. The NPs were incubated for two weeks to determine the release profiles of the proteins. At the end of the two week incubation period, it was observed that 49±1.3 % of hAng-1 and 59±2.1 % of hVEGF had been released from the NPs. The proliferation and percent apoptosis of HUVECs in response to the released proteins was observed. The results indicate that the released proteins were biologically active and the combined application demonstrated a significantly high proliferatory and antiapoptotic effect on HUVECs as compared to the effect demonstrated by the released individual proteins. These studies could serve as a basis to encourage further research into potential in vivo application of these protein loaded NPs in the field of therapeutic angiogenesis.
Journal: TechConnect Briefs
Volume: 3, Nanotechnology 2011: Bio Sensors, Instruments, Medical, Environment and Energy
Published: June 13, 2011
Pages: 183 - 185
Industry sectors: Advanced Materials & Manufacturing | Medical & Biotech